News Releases

29 Jul '19
Alvotech and Cipla Gulf FZ LLC (“Cipla Gulf”), a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited (BSE: 500087; NSE: CIPLA EQ; hereafter referred to as "Cipla"), today announced that Alvotech and Cipla Gulf have entered into an exclusive partnership for the
03 Jun '19
Alvotech and Abdi Ibrahim enter into an exclusive partnership for the development and commercialization of biosimilars in Turkey. Alvotech gains access to the fast-growing Turkish biosimilar market Abdi Ibrahim is Turkey’s leading pharmaceutical company having built the largest biotechnological
09 May '19
Alvotech today announced the appointment of Mark Levick as Chief Executive Officer, effective 5 August 2019. Mark brings over 18 years of global industry experience, with a very impressive track record of value creation and success in bringing new biosimilars to market.
09 Apr '19
Alvotech and Fuji pharma have entered into a binding agreement for the exclusive partnership and supply to commercialize Alvotech’s ustekinumab biosimilar (Stelara®) in Japan.  Alvotech and Fuji Pharma recently announced Fuji´s ~US$50 million investment into Alvotech that further strengthens the
13 Mar '19
Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA® Alvotech’s AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors 400
25 Feb '19
Following the late 2018 announcement that Alvotech was to enter into a joint venture with Changchun High & New Technology Industries Group Inc (“CCHN”), representatives from the two companies met up last week to discuss the groundbreaking of the new facility.
22 Jan '19
Fuels growth and biosimilar development in a fast-growing market Alvotech announced today that it has successfully raised US$300 million through a private bond offering. Net proceeds from the capital raised will be used to fuel continued growth, refinance of existing debt and the further
17 Dec '18
Biopharmaceutical company Alvotech announced today that Japan-based Fuji Pharma has acquired a 4.2% stake in the business for approximately US$50 million. Alvotech and Fuji Pharma recently announced an exclusive agreement for development and commercialization of biosimilars in Japan.
Displaying 41 - 50 of 55